EMI (Encore Medical) FCF Yield %: 0.00 (As of Jun. 25, 2026)


What is Encore Medical FCF Yield %?

Encore Medical EMI FCF Yield % is 0.00 as of Jun. 25, 2026.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Encore Medical's Trailing 12-Month Free Cash Flow is $0.00 Mil, and Market Cap is $0.00 Mil. Therefore, Encore Medical's FCF Yield % for today is 0.00%.

The historical rank and industry rank for Encore Medical's FCF Yield % or its related term are showing as below:


EMI's FCF Yield % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -0.37
* Ranked among companies with meaningful FCF Yield % only.

Encore Medical's FCF Margin % for the quarter that ended in Dec. 2025 was -19.38%.

Encore Medical FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Encore Medical FCF Yield % Related Terms

Encore Medical FCF Yield % Historical Data

* Premium members only.

The historical data trend for Encore Medical's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Encore Medical FCF Yield % Chart

Encore Medical Annual Data
Trend Dec23 Dec24 Dec25
FCF Yield %
0.00 0.00 0.00

Encore Medical Quarterly Data
Dec23 Sep24 Dec24 Jun25 Sep25 Dec25
FCF Yield % Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

EMI vs : FCF Yield % Comparison

For the Medical Instruments & Supplies subindustry, Encore Medical's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Encore Medical FCF Yield % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Encore Medical's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Encore Medical's FCF Yield % falls into.


Encore Medical FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Encore Medical's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-0.669 / 0
=N/A%

Encore Medical's annualized FCF Yield % for the quarter that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-0.251 * 4 / 0
=N/A%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of 0.00 mean?
Encore Medical (EMI) has a FCF Yield % of 0.00 as of Jun. 25, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Encore Medical and its competitors.
Is Encore Medical's FCF Yield % too high?
Encore Medical's current FCF Yield % is 0.00.
How does Encore Medical's FCF Yield % compare to ?
Encore Medical's FCF Yield % of 0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Encore Medical and its competitors. Encore Medical's current FCF Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Encore Medical stock overvalued right now?
Encore Medical (EMI) has a current FCF Yield % of 0.00. The current FCF Yield % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Encore Medical (EMI), the current FCF Yield % is 0.00 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Encore Medical Business Description

Comparable Companies
Address 2975 Lone Oak Drive, Suite 140, Eagan, MN, USA, 55121
Encore Medical Inc develops, manufactures, and markets septal occlusion devices for the repair of certain cardiac defects. Its products have been implanted in approximately 35,000 patients outside the United States. Its closure device is designed to correct a cardiac defect, generally diagnosed in adulthood, known as a patent foramen ovale (PFO). The company also currently market and sell septal occlusion devices for the transcatheter closure of atrial septal defects (ASD).